139
0 Kommentare
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA, the First and Only Oral Somatostatin Analog for Patients with Acromegaly - Seite 3
About Chiasma
Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing
treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop oral medications that are currently available
only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with
octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA,
TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.
Lesen Sie auch
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding the commercial launch and availability of MYCAPSSA, statements concerning the commercial or therapeutic potential of MYCAPSSA, the anticipated market acceptance of
and access to MYCAPSSA, and statements concerning capabilities of our sales team and the potential hiring of additional customer-facing employees. Such statements are subject to numerous important
factors, risks and uncertainties, many of which are beyond the company’s control, that may cause actual events or results to differ materially from the company’s current
expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could be affected by risks and uncertainties relating to a number of factors,
including the following: the acceptance of MYCAPSSA in the commercial marketplace, the timing and costs involved in establishing a commercial organization, Chiasma’s ability to obtain and maintain
necessary regulatory approvals, and the impact the ongoing COVID-19 pandemic may have on the company’s business, including its expected development, manufacturing, regulatory and
commercialization timelines for MYCAPSSA. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ
from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and in
subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this
information unless required by law.